Publication:
Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT.

cris.virtualsource.author-orcid657eb181-3137-4b10-9226-937f459da4de
cris.virtualsource.author-orcidf618d47b-2349-48a6-a9b4-74989a01812f
datacite.rightsopen.access
dc.contributor.authorMaul, Julia-Tatjana
dc.contributor.authorDjamei, Vahid
dc.contributor.authorKolios, Antonios G A
dc.contributor.authorMeier, Barbara
dc.contributor.authorCzernielewski, Justine
dc.contributor.authorJungo, Pascal
dc.contributor.authorYawalkar, Nikhil
dc.contributor.authorMainetti, Carlo
dc.contributor.authorLaffitte, Emmanuel
dc.contributor.authorSpehr, Christina
dc.contributor.authorAnliker, Mark
dc.contributor.authorStreit, Markus
dc.contributor.authorAugustin, Matthias
dc.contributor.authorRustenbach, Stephan
dc.contributor.authorConrad, Curdin
dc.contributor.authorHafner, Jürg
dc.contributor.authorBoehncke, Wolf-Henning
dc.contributor.authorBorradori, Luca
dc.contributor.authorGilliet, Michel
dc.contributor.authorItin, Peter
dc.contributor.authorFrench, Lars E
dc.contributor.authorHäusermann, Peter
dc.contributor.authorNavarini, Alexander A
dc.date.accessioned2024-10-25T05:52:32Z
dc.date.available2024-10-25T05:52:32Z
dc.date.issued2016
dc.description.abstractBACKGROUND The Swiss psoriasis registry SDNTT (Swiss Dermatology Network for Targeted Therapies) records the long-term safety and effectiveness of systemic treatment regimens for psoriasis. PATIENTS AND METHODS Patients with moderate to severe psoriasis are included in the SDNTT when treatment with a conventional systemic agent or biologic is initiated that was not previously used by the respective patient. Patients are followed over a 5-year period. Clinical data are obtained every 3-6 months using standardized case report forms. Here, baseline data and follow-up data for 1 year of patients included from October 2011 until December 2014 were analyzed. RESULTS Within 39 months, 323 patients from 7 tertiary dermatology centers in Switzerland were recruited in the SDNTT; 165 patients received biologics and 158 conventional systemic therapies. Patients treated with biologics had a significantly higher severity (PASI 11.3 vs. 9.2, BSA 15.6 vs.11.9, psoriatic arthritis 36.4 vs. 10.8%; p ≤ 0.005, p ≤ 0.013, p ≤ 0.001) and a longer duration of illness (19.2 vs. 14.4 years, p ≤ 0.003) compared to patients starting a conventional systemic treatment. PASI reduction was satisfying in both treatment groups, with 60.6% of patients treated with biologics achieving PASI75 after 1 year compared to 54.2% of patients receiving conventional systemic drugs (nonsignificant). On average, the drug survival in patients receiving a biologic therapy was significantly longer than those receiving conventional systemic treatments (30.5 vs. 19.2 months, p ≤ 0.001). CONCLUSIONS In the real-world setting of a prospective national therapy registry, the application of current therapeutic guidelines for patients with moderate to severe psoriasis resulted in a PASI reduction of approximately 70% within the first year of treatment, but current therapeutic targets of PASI75 and PASI90 were reached in only 58 and 36% of patients, respectively, at 1 year, highlighting a gap in efficacy between selective clinical trials and the real-world setting.
dc.description.numberOfPages8
dc.description.sponsorshipUniversitätsklinik für Dermatologie
dc.identifier.doi10.7892/boris.100049
dc.identifier.pmid28076860
dc.identifier.publisherDOI10.1159/000452740
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/152812
dc.language.isoen
dc.publisherKarger
dc.relation.ispartofDermatology
dc.relation.issn1018-8665
dc.relation.organizationDCD5A442BAD9E17DE0405C82790C4DE2
dc.subjectBiologics Conventional systemic treatment Psoriasis Swiss psoriasis registry
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.titleEfficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT.
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
oaire.citation.endPage647
oaire.citation.issue6
oaire.citation.startPage640
oaire.citation.volume232
oairecerif.author.affiliationUniversitätsklinik für Dermatologie
oairecerif.author.affiliationUniversitätsklinik für Dermatologie
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.date.embargoChanged2018-01-13 01:30:12
unibe.description.ispublishedpub
unibe.eprints.legacyId100049
unibe.journal.abbrevTitleDERMATOLOGY
unibe.refereedtrue
unibe.subtype.articlejournal

Files

Original bundle
Now showing 1 - 1 of 1
Name:
452740.pdf
Size:
158.27 KB
Format:
Adobe Portable Document Format
File Type:
text
License:
publisher
Content:
published

Collections